the aid library

LIST OPTIONS

Filter

4299

Identifying Early Adopters of COVID-19 Vaccines in Latin America

Arrieta, A.; A. García-Prado, J.P. Sarmiento, et al. Florida International University (2021) CC

COVID-19 vaccine hesitancy is currently one of the main obstacles to worldwide herd immunity and socioeconomic recovery. Because vaccine coverage can vary between and within countries, it is important to identify sources of variation so that policies can be tailored to different population groups. ... more

Contact tracing and quarantine in the context of COVID-19: interim guidance, 6 July 2022
recommended

World Health Organization WHO (2022) C_WHO

Contact tracing for COVID-19 is the process of identifying, assessing, and managing people who have been exposed to someone who has been infected with the SARS-CoV-2 virus, while quarantine is the separation of contacts from other people after exposure to a probable or confirmed case of SARS-CoV-2 i... more

Guideline for Preventive Chemotherapy for the Control of Taenia solium Taeniasis

Pan American Health Organisation PAHO (2021) C_WHO

The larval stage of the parasite Taenia solium can encyst in the central nervous system causing neurocysticercosis, which is the main cause of acquired epilepsy in the countries in which the parasite is endemic. Endemic areas are those with the presence (or likely presence) of the full life cycle of... more

External Link

Use of a Participatory Method for Community-Based Brucellosis Control Design in Agro-Pastoral Areas in Tanzania

Asakura S.; Makingi G.; John K. et al. Frontiers in Veterinary Science (2022) CC

Brucellosis is widespread in both humans and livestock in many developing countries. The authors have performed a series of epidemiological studies on brucellosis in agro-pastoral areas in Tanzania since 2015, with the aim of the disease control. Previously, the potential of a community-based brucel... more

External Link

Hendra virus: Epidemiology dynamics in relation to climate change, diagnostic tests and control measures

Yuen K. Y.; Frase N. S.; et al (2021) C2

Hendra virus (HeV) continues to pose a serious public health concern as spillover events occur sporadically. Terminally ill horses can exhibit a range of clinical signs including frothy nasal discharge, ataxia or forebrain signs. Early signs, if detected, can include depression, inappetence, colic o... more

Download (213)

View PDF (305)

Infection Prevention and Control (IPC) Standard Operating Procedure (SOP) for Training/Meetings in the context of COVID-19
recommended

African Union; Africa CDC Centres for Disease Control and Prevention (2022) CC

1.0 PURPOSE To define the procedure for the conduct of in-person meetings in both healthcare and community settings in response to COVID-19 and with respect to Public Health and Social Measures (PHSMs) to reduce the risk of disease transmission. A general risk assessment must be conducted to inform... more

Download (156)

View PDF (188)

Good practice statement on the use of variant-containing COVID-19 vaccines

World Health Organization WHO (2022) C_WHO

Declarations of interests were collected from all external contributors and assessed for any conflicts of interest. Summaries of the reported interests can be found on the SAGE meeting website and SAGE Covid-19 Working Group webpage. This guidance should be considered along with the broader COVID-... more

Download (118)

View PDF (142)

Clinical management of COVID-19: living guideline, 13 January 2023

World Health Organisation (WHO) (2023) C_WHO

As of 12 December 2022, over 645 million people worldwide have been diagnosed with COVID-19, with over 6.6 million deaths (4). The Omicron variant, which emerged in late November 2021, and its subvariants, are now the dominant circulating viruses, contributing to the ongoing surge in several countr... more

Download (163)

View PDF (184)

Infection prevention and control in the context of coronavirus disease (‎COVID-19)‎: a living guideline, 13 January 2023

World Health Organisation (WHO) (2023) C_WHO

The WHO continuously reviews available data on SARS-CoV-2 variants of concern. For this version, the global epidemiological situation of the COVID-19 pandemic as of 21 January 2022 – at a time when the Omicron VOC had been identified in 171 countries across all six WHO Regions and was rapidly re... more

Nigéria : réduire les causes indirectes de morbidité et de mortalité maternelle – le projet RICOM3

World Health Organisation (WHO) (2023) C_WHO

Le Nigéria a signalé son premier cas de COVID-19 vers fin février 2020. Le pays a ensuite connu quatre vagues de contaminations avec des pics en juin 2020, janvier 2021, août 2021 et décembre 2021. La pandémie de COVID-19 a eu de graves conséquences sur l’économie du Nigéria et a entra�... more

Nigeria: reducing the indirect causes of maternal morbidity and mortality: the RICOM3 Project

World Health Organisation (WHO) (2023) C_WHO

Nigeria reported its first case of COVID-19 at the end of February 2020 and subsequently experienced four waves, with peaks in June 2020 and January, August and December 2021. The COVID-19 pandemic severely impacted the economy of Nigeria and caused disruption of health services nationwide. During... more

External Link

Rabies Vaccine

Center for Disease Control and Prevention CDC (2014) CC

A regimen of four 1-mL doses of HDCV or PCEC vaccines should be administered intramuscularly to previously unvaccinated persons. The first dose of the four-dose course should be administered as soon as possible after exposure. Additional doses should be administered on days 3, 7, and 14 after the... more

External Link

Rabies - our time to act is now

World Health Organization WHO (2018) C_WHO

Rabies is an infectious viral disease that is almost always fatal once clinical symptoms appear. In most cases, the disease is transmitted to humans by the bite of a rabid dog, but infection can also spread through scratches or via saliva. Rabies kills one person every 9 minutes and children aged ... more

Download (143)

View PDF (155)

Haiti's Health Emergency Appeal 2023
recommended

World Health Organisation (WHO) (2023) C_WHO

For the past years, Haiti has been engulfed in a socioeconomic, political, and humanitarian crisis that has reached critical levels since mid-September 2022 with the intensification of gang violence and social unrest. The widespread insecurity and political instability have drastically affected the... more

External Link

Gavi Alliance MS Roadmap for Oral Cholera Vaccines 4: The Market Shaping Goal Ensure healthy markets for vaccines and related products

GAVI Alliance (2023) C1

Geneva, 22 May 2023 – Gavi, the Vaccine Alliance today published a roadmap* outlining critical actions needed to ensure supply of oral cholera vaccine (OCV) is able to meet growing demand from countries. Released against a backdrop of a recent wave of cholera outbreaks around the world, the roadma... more

Download (183)

View PDF (154)

Profil national de la fièvre jaune: Argentine

World Health Organisation (WHO) (2022) C_WHO

La fièvre jaune est endémique dans plusieurs pays d'Amérique latine. Afin d'aider les décideurs à hiérarchiser les actions de prévention contre cette maladie, l'Organisation panaméricaine de la santé présente ces profils de pays avec une sélection concise et complète de données provenan... more

External Link

Innovative financing instruments for global health 2002–15: a systematic analysis

Atun, R.; Silva, S.; Knaul, F.M. Lancet Global Health (2017) CC

Development assistance for health (DAH), the value of which peaked in 2013 and fell in 2015, is unlikely to rise substantially in the near future, increasing reliance on domestic and innovative financing sources to sustain health programmes in low-income and middle-income countries. We examined inno... more

Download (285)

View PDF (384)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (223)

View PDF (190)

Clinical management of diphtheria: guideline

World Health Organization WHO (2024) C_WHO

WHO has published the first-ever guidance on the clinical management of diphtheria. The only previously available guidance was an operational protocol. The new guidance followed the rigorous process for developing guidance at WHO. It addresses the use of Diphtheria Antitoxin (DAT) in the treatmen... more

Download (140)

View PDF (146)

Building better immunity: A life course approach to healthy longevity

Pan American Health Organization PAHO (2023) C_WHO

As the Americas undergo profound demographic change and there are more persons aged 65 years or older than children younger than 5 years, it is crucial to recognize that national immunization programs must be redesigned to ensure comprehensive protection for individuals across the lifespan. By adopt... more

Contact tracing and quarantine in the context of COVID-19: interim guidance, 6 July 2022 recommended

Infection Prevention and Control (IPC) Standard Operating Procedure (SOP) for Training/Meetings in the context of COVID-19 recommended

Haiti's Health Emergency Appeal 2023 recommended

Contact tracing and quarantine in the context of COVID-19: interim guidance, 6 July 2022
recommended

Infection Prevention and Control (IPC) Standard Operating Procedure (SOP) for Training/Meetings in the context of COVID-19
recommended

Haiti's Health Emergency Appeal 2023
recommended